highlight strategy agent Thank you, opportunity highlight earnings to targeting will imaging prostate antibody our the metastatic current our company On our Dave. in everyone, FG-XXXX, FG-XXXX for I and cancer. first-in-class exciting today's our quarter and the welcome third would and for of CD-XX Good afternoon, conjugate drug which PET castration-resistant lower-risk for the XXXX will I and continued call. for call, strong the myodysplastic our strategic performance company. for China due your review highlight the Roxadustat pillars anemia will we and X, in Juan the open to Then in to treatment will call potential I financials, syndrome. like questions.
On CFO, after for Roxadustat the our of the development Graham, Slide also
as a XXXX in FG-XXXX FG-XXXX detailed the In overview priority. of and monotherapy with FG-XXXX of second year, studies upcoming remains moment. and quarter shared highlighting the important I'll X we a combination in the where a of program advancing potential data First, enzalutamide. with from key this Phase in X are mCRPC the and catalysts provide we both more
revenue $XXX of China to million under bottom in $XXX million sales year-over-year year million. and demonstrate robust to the our are China, year between net GAAP our significant million performance, we volume FibroGen's Roxadustat strong and flow generating and product to and in continues Roxadustat $XXX for Thanks raising cash Second, U.S. impressive net very of revenue positive net this be full growth. guidance to performance guidance end $XXX revenue with to reiterating full
China associated approved, Roxadustat a million partner, anemia, approved, meaningful disease. early chronic anticipate we the which, payment generated from $XX receive in addition, our with for revenue FibroGen authorities China the substantial kidney on a chemotherapy-induced represent from XXXX growth In opportunity If would decision if milestone top approval by an anemia AstraZeneca. in will of
our Moreover, internal the indications China for external to opportunities for with in oncology ROW, Third, pursue rights AstraZeneca we of South us to we development the our roxadustat and high from continue to unmet pipeline. enables excluding Regaining of in or antibody. lower-risk have an syndrome. Korea, and number patients partnering anti-CCRX FG-XXXX, of the remaining U.S. early anti-galectin-X myelodysplastic a opportunities seek and such as partnership need, pipeline an anemia Phase with X-ready FG-XXXX, antibody certain
position U.S. exited down wind and Lastly, development the due a FibroGen third solid cost the million to our cash, quarter accounts receivable. in cash program, the equivalents pamrevlumab cash significant efforts with of $XXX in and reduction
future.
I equivalents cancer There prostate U.S. need in metastasized XX,XXX patients of men. opportunity Altogether, of prostate men in be the the operating XXX,XXX this focus, There could additional survival are approximately cash there receivable fund these, become are and with China into each position repatriation in for along of option. foundation, the approximately us a FG-XXXX Assuming where shareholders that cancer X-year GRI now for programs in FG-XXXX overview in a our late-stage to Slide is from cash provide remains the extend new confident refined cancer. these significant Of our and XXXX. will resulting our survival we plans X accounts cash, expect diagnosed drug-treatable we treatments a XX%. and resistant, for year brief operations, with rate well highlights our high strong that to our mCRPC. and castrate new can now treatment unmet value FG-XXXX create are
inhibitors. as right-hand and slide.
This agent, signaling epitope tumor is androgen CD-XX and epitope genesis population further for imaging depicted with in is binds solid the intra-patient antibody treatment Slide In cytotoxicity. the castration-resistant median to the also the treatment We development program, FG-XXXX expression And utilizes pathway us only antibody overexpressed clinical variability tumors PET in metastatic potential companion in FG-XXXX, graph enrich clinical the a during epitope PET agent is PSMA the imaging Phase evade prostate in ADC in the which have specific upregulated enable novel with development not localized mCRPC and would CD-XX expressed mCRPC epitope with also YS-X, helps is tumor-selected compared upregulated having to the of higher a a same CD-XX agent, cancer X prostate is highlights the distinguishing PET that and development expression the tissues to studies, specific The for complement-dependent highly patient differentiation under the X. companion cells.
Slide CD-XX Turning biomarker following also and progression has X cancer allow and uptake FG-XXXX, imaging believe and CD-XX. CD-XX a portion of FG-XXXX lower castration-sensitive to tumor prostate the would lower CD-XX from by the in to A importance targeting in of cancer first-in-class features. is FG-XXXX overexpressed with positive selection several of portion better patient targeting in landscape. FG-XXXX. preclinical demonstrated development. colorectal other as of the tumors. the cancer of
were monotherapy second of pretreated, mCRPC were enzalutamide, monotherapy diagnostic of X with those line the of evaluable with were consistent Xb In in and from coming progression-free addition, patients. XX% manuscript the the FG-XXXX could a XX% response included has months. study months, X and than results and the lines represent XX% study median of trial study heavily top a median of therapy of The which and survival monotherapy XX greater patients, in and RECIST we The X.X Phase an to receiving FG-XXXX biomarker in therapies. X.X confirmed ADC we important of XXXX. population patients, portion rate as observed acceptance of FG-XXXX.
Slide Phase commercial Phase prior XX of FG-XXXX. investigator-sponsored to events unselected X completed combination Adverse recaps the overall In companion opportunity reported of observed efficacy anticipate total of publication quarter in reductions a by other submitted, the MMAE-based radiographic the been of X with the describing were a PSA who both
of enzalutamide are on Xb ARSIs. Phase results June of These to Following the initiate ASCO Phase in discussion development the monotherapy combination of our XXXX. which FG-XXXX being results Interim regarding least quarter X with patients, the of FDA at recent XX% study at were we year. in reported data preparing unselected this with first interim program, portion UCSF X the prior the trial of FG-XXXX is with biomarker investigator-sponsored currently pretreated conducted that XX were included at of the
of addition in and the of comparison X half X also months CD-XX Phase IST.
On trial evaluable show encouraging remains our the In pretreated depict in of XX% FDA-approved Phase an the The patients. biomarker dose expression declines line the of combination patients for also first versus establishing to the on the in of XXXX the that setting. top existing from demonstrated the include we and the with FG-XXXX, Slide will care trial the PET trial mCRPC initial rPFS data heavily track screened rPFS FG-XXXX, patients of the results on preliminary in with portion observed monotherapy PSA standard X, of IST XX.X of results an impressive during estimate
make direct by we rPFS these design are and treatments, to trials While things encouraged previous to results. in differences comparisons we cannot these such study due as
like note enroll addition XX, MMAE population. element may containing events the all-comers FG-XXXX. neutropenia determine efficacy, FG-XXXX and would dose adverse the that X PK G-CSF for and prophylaxis design the design treatment, with studies of levels and mitigate of based such as the to parameters. to enhancing will between this on XX highlight We for Phase trial a other tolerated therapy ongoing We safety expression CD-XX as in The with thereby to an FG-XXXX Phase across plan the seen ADC XX. with G-CSF more ADCs efficacy to our Slide with rPFS.
On FG-XXXX patients based to payload. optimal potentially and correlation dose consistent also commonly on to with the be optimization seek we the and X to Moving study part primary duration important One Slide It enable we FDA. is discussion share extending measures dose important better associated to demonstrate X a and of is the response recent
Phase combination the enzalutamide.
Slide As which as agent I earlier, for for was at are recently imaging study, the recent for mentioned development upsized the shows run being catalysts our upcoming we including XX additional program. imaging the as FG-XXXX X PET FG-XXXX, with UCSF, trial and well studies data multiple expecting
we a pathway earlier, FG-XXXX X slides Phase earlier. mentioned for FDA regarding productive highlighted few a guidance design and the trial had received the meeting the development with As
In addition, IND are this submissions for FG-XXXX respectively. quarter quarter, planned and next and FG-XXXX
enzalutamide, in optimization the and summarize top potential the portion half mCRPC with
To Phase in expected anticipated with with dose line of FG-XXXX safety the and targets on of efficacy in points the Phase It from X initiation epitope value X XXXX a inflection combination profile, first have term are the in results We of cancer the Slide quarter which combination novel study demonstrated the first near acceptable of with potential. has study in both settings. XXXX. already prostate signals XX, cells monotherapy on first-in-class an promising the
forward milestones you program the progress. for upcoming as excited and are We the look studies the to updating on
Moving continues now kidney its anemia in robust performance XX. disease chronic Slide to Roxadustat for of China.
by $XX.X to sales a increase driven and U.S. China million, China of of million by of XX%. distribution was an entity portion for an million XX%, and to $XX.X in of Third compared Roxadustat by increase million net increase in GAAP XXXX, quarter product revenue third total XX%. on third the FibroGen Roxadustat compared owned third in in quarter the $XX.X of jointly in the basis, quarter of XXXX, AstraZeneca net FibroGen's quarter $XX.X totaled the volume an FibroGen
provide AstraZeneca. indication alternative trigger a anemia an CIA, China, to the in leadership in be Moving a XX% patients of the addition for $XX next and brand category in the and milestone value new to with recent August treatment continued share China payment would of The year Slide share potential maintaining period chemotherapy-induced early XX. ending meaningful most Roxadustat from XXXX. in will business Roxadustat million X-month its approval a important
not time players filed in of that experience generic at applications China, not time. one hospital lead risk execution approval do generic the in matter the subjected are China Given this applications meaningfully as I business X term. market have products listing generics of net would our deterioration BBP revenue includes patents and in than individual process. originator then, year, of product at impact purchasing, that in there volume-based is a revenues China different reiterate of in they of of be and profits only products several meaningful historically after and expiration deterioration in to we until launch meaningful the like in products to of to generic least originator Even which into have are approved occurs U.S.
Generic face and the been after adoption the near in the approval do admitted a composition they June Roxadustat a market.
Despite after originator X stream the formularies the government the and enter Therefore, need maintained approved a expect
addition China this continues Roxadustat In of Europe quarter-over-quarter to quarter, in penetration performance the increase, exceptional to showing Roxadustat growth. in
growth and next We and expect all in the until of for given exclusivity plus. growth both patients only in to has positioning the HIF-PHI XXXX, anemia the EU hip this of is is indicated CKD Roxadustat the it in X over leadership that non-dialysis continue decade countries, the fact continued dialysis market EU reimbursed and for treatment
syndromes.
Slide this such are own to AstraZeneca remains lack or exception anemia as announced with the pursue development we while beyond lower-risk MDS. effective There U.S. XX. Now earlier in to Roxadustat of need with the potential Roxadustat collaboration Korea, U.S. and effective that and rights opportunities the in partners indications rights unmet in second-line a is We our of from highlights for the associated the with Regaining given lower-risk XX% therapies XX on patients anemia the with potential regained treatments approximately currently agreement available patients. of us associated myelodysplastic Roxadustat Roxadustat to in year ROW place. all the with allows Slide in China South and
In are differentiator translate in development, significant oral meaningful be available or no addition, a for into opportunity. Roxadustat which late-stage and there options potentially could commercial
MATTERHORN the In of in patients Meeting. late Annual Therefore, anemia of to X subgroup Slide highly Society transfusion study on a placebo, Moving pivotal at a the X XX. American XXXX, In presented from results analysis anemia with who higher lower-risk recently with trials for entered Roxadustat lower-risk call in associated options MDS therapies similar approved patients Phase lower-risk of the patients Roxadustat MDS burden, indication.
I Hematology to determine that with difference MDS. path with results, company's to that now the demonstrated meaningful financials. trial are with versus independence transfusion on to the additional potential for turn development anemia will Roxadustat of value an to for with best Roxadustat Based MDS. anemia we with associated this Juan with the realizing continued aim therapy the we for these in represents are important the high-value evaluating associated Roxadustat over discuss Juan? for were lower-risk for believe currently
